Health Care | Pharmaceuticals, Biotechnology & Life Sciences | Biotechnology
NASDAQ | Common Stock
Comera Life Sciences Holdings, Inc., a preclinical stage life sciences company, develops an internal portfolio of proprietary therapeutics that incorporate its proprietary formulation platform.
Its SQore platform is designed to enable the conversion of intravenous biologics to subcutaneous versions.
The company's lead pipeline candidate is CLS-001, a subcutaneous formulation of vedolizumab for the treatment of inflammatory bowel disease, including Crohn's disease and ulcerative colitis.
Comera Life Sciences Holdings, Inc. was founded in 2014 and is headquartered in Woburn, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 136.31 K Decreased by -41.98% | -2.15 M Increased by +40.48% | Decreased by -1.58 K% Decreased by -2.58% |
| Jun 30, 23 | 315.06 K Increased by +114.72% | -1.41 M Increased by +90.06% | Decreased by -448.06% Increased by +95.37% |
| Mar 31, 23 | 392.92 K Increased by +312.15% | -77.77 M Decreased by -2.25 K% | Decreased by -19.79 K% Decreased by -470.75% |
| Dec 31, 22 | 156.12 K Increased by +112.89% | -2.92 M Decreased by -44.07% | Decreased by -1.87 K% Increased by +32.33% |
| Sep 30, 22 | 234.92 K Increased by +167.67% | -3.62 M Decreased by -296.00% | Decreased by -1.54 K% Decreased by -47.95% |
| Jun 30, 22 | 146.73 K Increased by +106.90% | -14.20 M Decreased by -616.85% | Decreased by -9.68 K% Decreased by -246.47% |
| Mar 31, 22 | 95.33 K - | -3.31 M - | Decreased by -3.47 K% - |
| Dec 31, 21 | 73.33 K - | -2.02 M - | Decreased by -2.76 K% - |